Clinical Data

Clinical Data for iStent infinite®

Intermediate Therapy That Excels Where Other Treatments Have Failed

In the prospective, multicenter, 12-month pivotal trial, patients with open-angle glaucoma who had failed prior surgical intervention underwent standalone iStent infinite® implantation.1

Of note, patients enrolled in this study had a significantly higher preoperative treatment burden with more severe glaucoma as compared to other trabecular bypass MIGS pivotal trials.1,3,5

Learn about the INTEGRITY study

The first prospective, randomized, multinational, integral head-to-head study comparing iStent infinite vs Hydrus Microstent in a standalone procedure

Learn More

Average patient characteristics in the iStent infinite® pivotal trial1:

Despite this tough-to-treat population, iStent infinite® delivered exceptional results demonstrating sustained efficacy throughout the course of the study.1

* Reduction from baseline at 12 months on the same or fewer medications.

Safety Without Compromise in Tough-to-Treat Patients Prone to Complications

In the 12-month pivotal trial, exceptional intraoperative and postoperative safety was demonstrated among patients with 2 or more failed filtering surgeries1,4:

Safety

For a complete list of postoperative adverse events, please review the Important Safety Information in the Instructions for Use.

  1. Glaukos Data on File
  2. Malihi M, Moura Filho ER, Hodge DO, Sit AJ. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Ophthalmology. 2014;121(1):134–41
  3. CyPass. Summary of safety and effectiveness data. Alcon Laboratories, Inc; 2016.
  4. iStent infinite. Instructions for use. Glaukos Corporation; 2022.
  5. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology. 2019;126(1):29-37.

Please Select Your Country

Continue